New drug duo shows promise against tough cancers
NCT ID NCT05516914
First seen Dec 10, 2025 · Last updated Jun 24, 2026 · Updated 23 times
Summary
This study tested a combination of two drugs, LBL-007 and tislelizumab, in 98 adults with advanced solid tumors. The goal was to see if the combo is safe, tolerable, and effective at shrinking tumors. Researchers also looked at how the drugs move through the body and whether they trigger an immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Anhui Cancer Hospital
Hefei, Anhui, 230031, China
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350001, China
-
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, 530000, China
-
Hubei Cancer Hospital
Wuhan, Hubei, 430000, China
-
Huizhou Municipal Central Hospital
Huizhou, Guangdong, 516000, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410000, China
-
Jiangxi Cancer Hospital
Nanchang, Jiangxi, 330029, China
-
Sun Yat-Sen Memorial Hospital，Sun Yat-Sen University
Guangzhou, Guangdong, 510120, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530021, China
-
The First People's Hospital of Yu Lin
Yulin, Guangxi, 537000, China
-
The Second Affiliated Hospital of Hainan Medical University
Haikou, Hainan, 570000, China
-
Union Hospital Tongji Medical College Huazhong University of Science And Technology
Wuhan, Hubei, 430022, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
-
Zhejiang Cancer Hospital
Hangzhou, Hangzhou, 310000, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LBL-007 combined with tislelizumab (and sometimes chemotherapy drugs like cisplatin, gemcitabine, or docetaxel)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced solid tumors that are hard to treat.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 98 participants, so results may not apply broadly. Side effects from combining these drugs are not yet fully known.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.